|
1
|
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
|
N Engl J Med
|
2005
|
15.30
|
|
2
|
International staging system for multiple myeloma.
|
J Clin Oncol
|
2005
|
11.29
|
|
3
|
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
|
N Engl J Med
|
2013
|
6.21
|
|
4
|
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
|
N Engl J Med
|
2012
|
5.16
|
|
5
|
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
|
Lancet Oncol
|
2010
|
4.10
|
|
6
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
|
Blood
|
2007
|
3.66
|
|
7
|
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
|
J Clin Oncol
|
2007
|
3.54
|
|
8
|
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
|
Blood
|
2011
|
2.82
|
|
9
|
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
|
Blood
|
2008
|
2.74
|
|
10
|
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
|
J Clin Oncol
|
2010
|
2.58
|
|
11
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
|
Blood
|
2006
|
2.51
|
|
12
|
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
|
Blood
|
2012
|
2.42
|
|
13
|
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
|
Blood
|
2008
|
2.34
|
|
14
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
|
Br J Haematol
|
2009
|
2.32
|
|
15
|
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.
|
J Clin Oncol
|
2008
|
2.30
|
|
16
|
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
|
Blood
|
2011
|
2.13
|
|
17
|
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
|
J Clin Oncol
|
2008
|
2.09
|
|
18
|
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
|
Haematologica
|
2002
|
2.08
|
|
19
|
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
|
Blood
|
2011
|
1.94
|
|
20
|
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
|
J Clin Oncol
|
2013
|
1.79
|
|
21
|
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
|
J Clin Oncol
|
2011
|
1.78
|
|
22
|
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition.
|
Blood
|
2009
|
1.76
|
|
23
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
|
Blood
|
2011
|
1.75
|
|
24
|
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
|
Br J Haematol
|
2013
|
1.70
|
|
25
|
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
|
J Clin Oncol
|
2008
|
1.53
|
|
26
|
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
|
Br J Haematol
|
2008
|
1.52
|
|
27
|
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
|
Cancer Treat Rev
|
2010
|
1.48
|
|
28
|
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2006
|
1.44
|
|
29
|
Extramedullary multiple myeloma escapes the effect of thalidomide.
|
Haematologica
|
2004
|
1.42
|
|
30
|
[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].
|
Med Clin (Barc)
|
2009
|
1.40
|
|
31
|
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
|
J Clin Oncol
|
2013
|
1.39
|
|
32
|
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
|
J Clin Oncol
|
2007
|
1.29
|
|
33
|
Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.
|
Mayo Clin Proc
|
2007
|
1.27
|
|
34
|
Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
|
Arch Intern Med
|
2005
|
1.26
|
|
35
|
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
|
Lancet Oncol
|
2010
|
1.23
|
|
36
|
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
|
Blood
|
2002
|
1.21
|
|
37
|
Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
|
Clin Cancer Res
|
2005
|
1.21
|
|
38
|
Survival and years of life lost in different age cohorts of patients with multiple myeloma.
|
J Clin Oncol
|
2010
|
1.20
|
|
39
|
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
|
Br J Haematol
|
2008
|
1.20
|
|
40
|
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
|
Eur J Haematol
|
2006
|
1.20
|
|
41
|
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
|
Blood
|
2012
|
1.19
|
|
42
|
Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
|
Br J Haematol
|
2005
|
1.17
|
|
43
|
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents.
|
Haematologica
|
2010
|
1.14
|
|
44
|
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
|
Cancer
|
2008
|
1.13
|
|
45
|
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
|
Blood
|
2009
|
1.10
|
|
46
|
A practical update on the use of bortezomib in the management of multiple myeloma.
|
Oncologist
|
2006
|
1.09
|
|
47
|
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
|
Haematologica
|
2009
|
1.08
|
|
48
|
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
|
Blood
|
2012
|
1.07
|
|
49
|
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
|
Biol Blood Marrow Transplant
|
2007
|
1.06
|
|
50
|
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
|
Haematologica
|
2008
|
1.06
|
|
51
|
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
|
Oncologist
|
2011
|
1.06
|
|
52
|
Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
|
Clin Cancer Res
|
2012
|
1.05
|
|
53
|
Current multiple myeloma treatment strategies with novel agents: a European perspective.
|
Oncologist
|
2010
|
1.04
|
|
54
|
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
|
Cytokine
|
2008
|
1.04
|
|
55
|
Extramedullary involvement in multiple myeloma.
|
Haematologica
|
2012
|
1.03
|
|
56
|
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
|
Blood
|
2011
|
1.03
|
|
57
|
European perspective on multiple myeloma treatment strategies: update following recent congresses.
|
Oncologist
|
2012
|
0.98
|
|
58
|
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
|
Br J Haematol
|
2002
|
0.97
|
|
59
|
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
|
Blood
|
2014
|
0.96
|
|
60
|
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
0.96
|
|
61
|
Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.
|
Haematologica
|
2013
|
0.94
|
|
62
|
Bortezomib is an efficient agent in plasma cell leukemias.
|
Int J Cancer
|
2005
|
0.93
|
|
63
|
Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
|
Biol Blood Marrow Transplant
|
2012
|
0.92
|
|
64
|
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
|
Am J Hematol
|
2015
|
0.92
|
|
65
|
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
|
Haematologica
|
2010
|
0.90
|
|
66
|
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
|
Ann Hematol
|
2010
|
0.90
|
|
67
|
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
|
Clin Cancer Res
|
2010
|
0.89
|
|
68
|
Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
|
Eur J Haematol
|
2006
|
0.89
|
|
69
|
Changing paradigms in the treatment of multiple myeloma.
|
Haematologica
|
2009
|
0.87
|
|
70
|
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
|
Cancer
|
2011
|
0.86
|
|
71
|
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
|
Leuk Res
|
2011
|
0.84
|
|
72
|
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
|
Haematologica
|
2006
|
0.84
|
|
73
|
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
|
Am J Pathol
|
2012
|
0.84
|
|
74
|
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.
|
Haematologica
|
2011
|
0.84
|
|
75
|
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
|
Haematologica
|
2011
|
0.84
|
|
76
|
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
|
Eur J Haematol
|
2008
|
0.83
|
|
77
|
Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.82
|
|
78
|
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
|
Eur J Haematol
|
2012
|
0.81
|
|
79
|
Acquired Fanconi syndrome secondary to monoclonal gammopathies: a case series from a single center.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.81
|
|
80
|
Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures.
|
Eur J Haematol
|
2010
|
0.81
|
|
81
|
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
|
Cytokine
|
2004
|
0.81
|
|
82
|
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
|
Ann Hematol
|
2013
|
0.81
|
|
83
|
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
|
Eur J Haematol
|
2006
|
0.80
|
|
84
|
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
|
Adv Chronic Kidney Dis
|
2012
|
0.80
|
|
85
|
Novel approaches for reducing free light chains in patients with myeloma kidney.
|
Nat Rev Nephrol
|
2012
|
0.80
|
|
86
|
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
|
Leuk Res
|
2013
|
0.80
|
|
87
|
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways.
|
Haematologica
|
2009
|
0.79
|
|
88
|
[Autologous haematopoietic stem cell transplantation in POEMS syndrome: results in 4 cases].
|
Med Clin (Barc)
|
2007
|
0.79
|
|
89
|
Moving forward in myeloma research.
|
Haematologica
|
2004
|
0.79
|
|
90
|
Incorporating monoclonal antibodies into the therapy of multiple myeloma.
|
J Clin Oncol
|
2012
|
0.78
|
|
91
|
Perspective on the current use of bortezomib in multiple myeloma.
|
Haematologica
|
2006
|
0.77
|
|
92
|
Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
|
Clin Lymphoma Myeloma
|
2008
|
0.77
|
|
93
|
Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
|
Biol Blood Marrow Transplant
|
2011
|
0.77
|
|
94
|
The comprehensive clinical management of multiple myeloma and related-plasma cell disorders.
|
Expert Rev Hematol
|
2014
|
0.77
|
|
95
|
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.
|
Br J Haematol
|
2013
|
0.76
|
|
96
|
Response evaluation and monitoring of multiple myeloma.
|
Expert Rev Hematol
|
2014
|
0.76
|
|
97
|
Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
98
|
Re: When you look matters: the effect of assessment schedule on progression-free survival.
|
J Natl Cancer Inst
|
2008
|
0.75
|
|
99
|
Novel drugs for the treatment of multiple myeloma.
|
Haematologica
|
2010
|
0.75
|
|
100
|
Extramedullary myeloma spread triggered by surgical procedures: an emerging entity?
|
Acta Haematol
|
2014
|
0.75
|
|
101
|
On the "significance" of monoclonal gammopathy of undetermined significance.
|
Mayo Clin Proc
|
2004
|
0.75
|
|
102
|
Issues of front-line therapy for multiple myeloma--the standard of care.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
103
|
Monoclonal gammopathy of undetermined significance.
|
N Engl J Med
|
2002
|
0.75
|
|
104
|
How to treat multiple myeloma: thoughts on a multicentre survey in Germany.
|
Onkologie
|
2010
|
0.75
|
|
105
|
Cytoplasmic inclusions in leukocytes associated to cryoglobulinemia and IgG-kappa monoclonal gammapathy of undetermined significance.
|
Eur J Haematol
|
2011
|
0.75
|
|
106
|
Bortezomib-induced rhabdomyolysis in multiple myeloma.
|
Acta Haematol
|
2006
|
0.75
|
|
107
|
Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
|
Eur J Haematol
|
2008
|
0.75
|